RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celldex Therapeutics Stock

Celldex Therapeutics ROA 2024

Celldex Therapeutics ROA

-0.3

Ticker

CLDX

ISIN

US15117B2025

WKN

A2PEAB

In 2024, Celldex Therapeutics's return on assets (ROA) was -0.3, a -4.63% increase from the -0.32 ROA in the previous year.

Celldex Therapeutics Aktienanalyse

What does Celldex Therapeutics do?

Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Celldex Therapeutics's Return on Assets (ROA)

Celldex Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Celldex Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Celldex Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Celldex Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Celldex Therapeutics stock

What is the Return on Assets (ROA) of Celldex Therapeutics this year?

The Return on Assets (ROA) of Celldex Therapeutics is -0.3 undefined this year.

What was the ROA of Celldex Therapeutics compared to the previous year?

The ROA of Celldex Therapeutics has increased by -4.63% compared to the previous year.

What consequences do high ROA have for investors of Celldex Therapeutics?

A high ROA is advantageous for investors of Celldex Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Celldex Therapeutics?

A low ROA can be unfavorable for investors of Celldex Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Celldex Therapeutics affect the company?

An increase in ROA of Celldex Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Celldex Therapeutics impact the company?

A reduction in the ROA of Celldex Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Celldex Therapeutics?

Some factors that can influence the ROA of Celldex Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Celldex Therapeutics important for investors?

The ROA of Celldex Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Celldex Therapeutics take to improve ROA?

To improve ROA, Celldex Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Celldex Therapeutics pay?

Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Celldex Therapeutics?

The current dividend yield of Celldex Therapeutics is .

When does Celldex Therapeutics pay dividends?

Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celldex Therapeutics?

Celldex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Celldex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celldex Therapeutics located?

Celldex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celldex Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Celldex Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Celldex Therapeutics in the year 2023?

In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.

In which currency does Celldex Therapeutics pay out the dividend?

The dividends of Celldex Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Celldex Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Celldex Therapeutics

Our stock analysis for Celldex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celldex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.